Muhammhad Shahzeb Khan

Nephrology — Baylor Scott & White Health, United States

LeadR Profile

Muhammhad Shahzeb Khan Baylor Scott & White Health United States
2 383 ScienceLeadR Reputation 2383
Network Map

Nephrology

Subspecialties: Cardiology

Full career Last 3 years

Main Topics

Publications and Clinical Studies

Publications Clinical Studies

Short Biography

Dr. Khan is an internationally recognized expert in cardiometabolic diseases, cardio-oncology and heart failure. He has authored and co-authored more than 400 peer reviewed publications. He is involved in various pivotal clinical trials, and is an associate editor of Heart Failure Reviews and European Society of Cardiology-Heart Failure. Dr. Khan is strongly committed to compassionate patient care with a focus on quality of life and patient preference. Dr. Khan is board certified in cardiovascular diseases, with sub-specialty board certification in all cardiac imaging modalities including Echocardiography, Cardiac CT, Cardiac MRI, Nuclear Imaging and Vascular Ultrasound. Dr Khan is frequently invited to speak at national and international conferences on various preventive cardiology topics including obesity, lipids, and diabetes. His work has been published in world’s most prestigious journals such as New England Journal of Medicine, JAMA, Lancet, Nature Reviews Cardiology, Circulation and Journal of American College of Cardiology. His research focuses on drug development and clinical trials of cardiometabolic therapies.

Organizations

Source: Pubmed

Baylor College of Medicine

Publications Synthesis

Source: Pubmed

Number : 600

Citations

Citations: 48 090 1st author: 163 Last author: 65 Unique author: 0

Main journals

J Am Coll Cardiol 48
Eur J Heart Fail 43
Am J Cardiol 37
JACC Heart Fail 28
J Card Fail 21

Best Journals

Lancet 16
Eur Heart J 9
Circulation 7

Breakdown by type

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Lactate Dehydrogenase as a Systemic Biomarker: Revisiting an Old Marker for Heart Failure.
oxidoreductases, heart failure, heart, disease progression, biomarkers, heart failure, systolic, l-lactate dehydrogenase, prognosis
JACC Heart Fail20261
Population estimates, trends, characteristics and prognostic outcomes of cardiovascular-kidney-liver-metabolic health: A population-based study.
mortality, phenotype, kidney, liver, obesity
Am J Prev Cardiol20262
iCARDIO Alliance global implementation guidelines for the management of obesity 2025 focus on prevention and treatment of cardiometabolic disease.
obesity management, obesity, therapeutics
Am J Prev Cardiol20262
Reply to commentary on 'effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular kidney-metabolic comorbidity'.
glucagon-like peptide 1, comorbidity, glucagon-like peptide-1 receptor, heart failure, heart, kidney, glucagon, glucagon-like peptides
Eur J Heart Fail20260
Heart Failure Prevention: Evidence Generation, Trial Design, and Regulatory Pathways.
mortality, hospitalization, heart failure, heart, cardiology, primary prevention, morbidity, therapeutics
J Am Coll Cardiol20260

Clinical Studies 9

Source: ClinicalTrials

Synthesis

By phase:

Phase 3 4
Phase 4 3
N/A 2

By status:

Completed 8
Recruiting 1

By type:

Interventional 9

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 1
multicentricup10 7

Main Topics

Cardiovascular Diseases 7

Cohort/Consortium Investigators 3

LeadR Networks

Main global connection map

Source: Pubmed Source: ClinicalTrials